Royal Philips has reported positive two-year results from the ILLUMENATE European randomised clinical trial (EU RCT) of the Stellarex 0.035” drug-coated balloon (DCB) to treat peripheral arterial disease (PAD).

Designed to restore and maintain blood flow to arteries, the Stellarex DCB was originally launched by Spectranetics, which was acquired by Philips last month.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The ILLUMENATE trial compared Stellarex with an uncoated balloon angioplasty in 328 patients at 18 centres in Germany and Austria.

Demonstrating the efficacy of Stellarex, the results showed maintenance of blood flow through the treated segment of the diseased artery in 75.9% of patients at 24 months, compared to 61% with an uncoated balloon.

"The addition of Stellarex in the Philips portfolio through the Spectranetics acquisition reinforces our commitment to helping physicians decide, guide, treat and confirm the right therapy for their patients."

The results are said to indicate higher efficacy, patency results, and longer treatment durability for Stellarex.

See Also:

Royal Philips Image-Guided Therapy Devices business leader Christopher Barys said: “The addition of Stellarex in the Philips portfolio through the Spectranetics acquisition reinforces our commitment to helping physicians decide, guide, treat and confirm the right therapy for their patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Assessments for the ILLUMENATE EU RCT were performed by angiographic and duplex ultrasound core laboratories, while funding was provided by Philips Spectranetics.

The trial is part of the ILLUMENATE series that comprised five studies for the evaluation of the Stellarex DCB in different groups of patients compared to an uncoated percutaneous transluminal angioplasty (PTA) balloon.